Heart Protein RND3 Shields Against Heart Attack Damage by Fixing Fuel Metabolism
A newly discovered mitochondrial protein boosts cardiac glucose burning and dramatically reduces heart injury after ischemia-reperfusion.
Summary
Scientists have identified RND3, a small protein found inside heart cell mitochondria, as a critical regulator of how the heart burns glucose for energy. In mouse models, deleting RND3 from heart cells caused the heart to shift away from efficient glucose metabolism toward fatty acid burning, leading to dysfunction and higher death rates. After a heart attack and reperfusion event, RND3 levels naturally drop — making the heart more vulnerable. Boosting RND3, on the other hand, protected heart tissue by preserving energy levels. The protein works by blocking an enzyme called ACAT1 from suppressing a key glucose-processing enzyme, PDHA1. These findings suggest that restoring RND3 activity could be a new therapeutic approach to limit heart damage during and after heart attacks.
Detailed Summary
Heart attacks remain a leading cause of death worldwide, and much of the damage occurs not during the blockage itself but during reperfusion — when blood flow is restored and triggers a cascade of metabolic and oxidative injury. Understanding and correcting the metabolic disturbances that occur during ischemia-reperfusion (I/R) injury is an urgent clinical priority.
Researchers at Chinese PLA General Hospital and Air Force Medical University investigated RND3, a small GTPase protein previously known for its role in cytoskeletal signaling. Their central discovery was that RND3 is also located inside mitochondria — the energy-producing organelles of heart cells — where it plays a previously unknown role in regulating glucose metabolism. Using cardiomyocyte-specific knockout and overexpression mouse models, the team mapped this function with precision.
When RND3 was deleted from heart cells, glucose oxidation fell sharply and fatty acid oxidation increased to compensate. This metabolic shift is energetically inefficient under stress conditions. The knockout mice also showed impaired mitochondrial respiration, uncoupling between glycolysis and the TCA cycle, reduced ATP and phosphocreatine levels, and dramatically worse outcomes after I/R injury. Mechanistically, RND3 physically binds to ACAT1, an enzyme that normally inhibits PDHA1 — the gateway enzyme that converts pyruvate into the TCA cycle. By blocking ACAT1, RND3 keeps PDHA1 active and glucose oxidation running. In human and mouse hearts after I/R, RND3 levels were significantly reduced, amplifying vulnerability. Overexpression of RND3 conferred strong cardioprotection, an effect that disappeared when PDHA1 was simultaneously knocked down, confirming the pathway.
These findings identify a novel mitochondrial axis that links metabolic flexibility to cardiac resilience. Therapeutically restoring RND3 — via gene therapy or small molecules that mimic its ACAT1-blocking function — could represent a meaningful strategy to reduce heart attack damage in clinical settings. The work warrants follow-up in large animal models and ultimately human trials.
Key Findings
- RND3 is a mitochondria-localized protein that promotes cardiac glucose oxidation by blocking ACAT1 from suppressing PDHA1.
- Deleting RND3 in heart cells causes metabolic dysfunction, reduced ATP, and higher mortality after ischemia-reperfusion injury.
- RND3 levels drop significantly in human and mouse hearts following heart attack, increasing metabolic vulnerability.
- Overexpressing RND3 in heart cells protected against I/R injury; this protection was lost when PDHA1 was knocked down.
- Therapeutic reconstitution of RND3 is proposed as a strategy to restore cardiac metabolic homeostasis post-ischemia.
Methodology
The study used cardiomyocyte-specific Rnd3 knockout and overexpression mouse models with left anterior descending coronary artery ligation to model I/R injury. Cardiac metabolism was assessed using 13C-NMR, 18F-FDG PET/CT, Seahorse mitochondrial assays, and 13C-metabolic flux tracing. Mechanistic dissection relied on RNA sequencing, coimmunoprecipitation, mass spectrometry, and GST pulldown assays.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, so mechanistic details and supplementary data cannot be fully evaluated. All primary experiments were conducted in mice; human validation is limited to observational expression data. Translation to clinical therapy requires large animal studies and eventual human trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.